Global pharmaceutical companies persist in their presence on the Russian market, providing their products even in a challenging geopolitical climate. This was revealed by the Executive Director of the Association of International Pharmaceutical Manufacturers (AIPM) in an interview with RG Larisa Matveeva.
Interview with Larisa Matveeva, Executive Director of the Association of International Pharmaceutical Manufacturers for Rossiyskaya Gazeta
Author: Dmitry Balta
Author: Dmitry Balta
According to Larisa Matveeva, the industry remains in a state of equilibrium, with all parties willing to engage in open dialogue and find common ground. This is the context in which all industry events at the SPIEF take place. It is crucial that companies themselves introduce new products to the market and continue to provide existing ones that are already familiar to domestic consumers.
«To this day, global companies remain active in Russia. In recent times, they have adjusted their operational procedures, and shipments are being made despite the proliferation of rumors about the departure of certain businesses. I can confidently assert that international companies have not exited the market», she emphasized during her conversation with RG.
Larisa Matveeva also presented the findings of a recent survey she undertook in collaboration with Skolkovo experts. She highlights that two-thirds of the companies intend to broaden their portfolios in the Russian market, and a total of 96% of the companies are maintaining or enhancing their operations.
Simplified rules for access of international innovative drugs to the Russian market should become an important innovation of the Russian legal system in the near future. President Vladimir Putin instructed the Ministry of Health of the Russian Federation to work on this issue earlier.
«We require a comprehensive strategy. To expedite the delivery of innovations to patients, it is crucial that decisions at each stage of the medicine’s lifecycle — from registration to public procurement — are clear and consistent. Particular emphasis must be placed on safeguarding intellectual property. All our recommendations on this matter have been submitted to the Ministry,», Larisa Matveeva stressed.
«To this day, global companies remain active in Russia. In recent times, they have adjusted their operational procedures, and shipments are being made despite the proliferation of rumors about the departure of certain businesses. I can confidently assert that international companies have not exited the market», she emphasized during her conversation with RG.
Larisa Matveeva also presented the findings of a recent survey she undertook in collaboration with Skolkovo experts. She highlights that two-thirds of the companies intend to broaden their portfolios in the Russian market, and a total of 96% of the companies are maintaining or enhancing their operations.
Simplified rules for access of international innovative drugs to the Russian market should become an important innovation of the Russian legal system in the near future. President Vladimir Putin instructed the Ministry of Health of the Russian Federation to work on this issue earlier.
«We require a comprehensive strategy. To expedite the delivery of innovations to patients, it is crucial that decisions at each stage of the medicine’s lifecycle — from registration to public procurement — are clear and consistent. Particular emphasis must be placed on safeguarding intellectual property. All our recommendations on this matter have been submitted to the Ministry,», Larisa Matveeva stressed.
Resource: Rossiyskaya Gazeta